Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2025-05-13 00:00:00 ET · period of report 2025-05-12 · accession 0001933414-25-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-13 | 2025-05-12 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $1.08 | +6,349 | 118.0K | +6% | +$6,857 |
| D | 2025-05-13 | 2025-05-12 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -6,349 | 101.6K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-12 | M | A | 6,349 | $1.08 | 118,035 | D | — | — | |
| 2 | Derivative | Stock Option | 2025-05-12 | M | D | 6,349 | $0.00 | 101,577 | D | $1.08 · — to 2032-07-11 | 6,349 Common Stock | (F2) The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. |